<DOC>
	<DOC>NCT00775658</DOC>
	<brief_summary>Use of olopatadine ophthalmic solution (eye drops) will decrease allergy skin test reactivity.</brief_summary>
	<brief_title>Olopatadine Eye Drops and Allergy Skin Testing</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis, Allergic</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Olopatadine Hydrochloride</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Adults aged 18 to 75 years Healthy volunteers (no major illnesses or active symptoms) Known allergy or hypersensitivity to the drugs or components Pregnant or nursing women Women wishing to become pregnant during the study's duration Use of topical or oral medications with antihistaminic activity for 14 days proceeding randomization Dermatographism as evidenced on skin testing on visit 1 Chronic urticaria active within the past 6 months Severe hypertension Psychiatric diagnoses which could potentially affect medication compliance, such as schizophrenia or delusional disorders, as determined by the investigator obtaining informed consent and based on the subject's past medical history Inability to provide informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>allergy</keyword>
	<keyword>skin testing</keyword>
	<keyword>eye drops</keyword>
	<keyword>antihistamines</keyword>
</DOC>